Precigen (NASDAQ:PGEN) CFO Harry Jr. Thomasian Sells 28,571 Shares

Precigen, Inc. (NASDAQ:PGEN) CFO Harry Jr. Thomasian sold 28,571 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $5.78, for a total value of $165,140.38. Following the completion of the transaction, the chief financial officer owned 525,964 shares in the company, valued at $3,040,071.92. This trade represents a 5.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harry Jr. Thomasian also recently made the following trade(s):

• On Wednesday, July 1st, Harry Jr. Thomasian sold 171,429 shares of Precigen stock. The stock was sold at an average price of $5.53, for a total transaction of $948,002.37.
• On Thursday, May 28th, Harry Jr. Thomasian sold 41,884 shares of Precigen stock. The shares were sold at an average price of $4.36, for a total value of $182,614.24.

Precigen Price Performance

PGEN stock traded down $0.45 on Wednesday, reaching $5.25. 7,446,304 shares of the company’s stock were exchanged, compared to its average volume of 4,558,847. The company has a quick ratio of 4.12, a current ratio of 4.82 and a debt-to-equity ratio of 4.62. Precigen, Inc. has a twelve month low of $1.45 and a twelve month high of $6.04. The firm has a market cap of $1.87 billion, a PE ratio of -4.45 and a beta of 1.06. The stock has a fifty day moving average of $4.40 and a 200-day moving average of $4.21.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. Precigen had a negative net margin of 646.99% and a positive return on equity of 717.50%. The business had revenue of $23.25 million during the quarter, compared to the consensus estimate of $20.81 million. As a group, equities analysts predict that Precigen, Inc. will post -0.02 EPS for the current fiscal year.

Hedge Funds Weigh In On Precigen

Large investors have recently bought and sold shares of the stock. State of Wyoming acquired a new position in shares of Precigen during the first quarter valued at approximately $27,000. NBC Securities Inc. acquired a new position in shares of Precigen in the fourth quarter worth about $38,000. Mason Investment Advisory Services Inc. acquired a new stake in shares of Precigen in the fourth quarter worth $42,000. Abel Hall LLC purchased a new position in Precigen during the fourth quarter valued at approximately $44,000. Finally, Royal Bank of Canada lifted its holdings in shares of Precigen by 102.6% during the 1st quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 5,426 shares during the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on PGEN shares. Wall Street Zen downgraded Precigen from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st. Citigroup reissued an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. HC Wainwright increased their price objective on shares of Precigen from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, May 28th. Zacks Research upgraded Precigen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Finally, Citizens Jmp upped their price target on shares of Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a report on Thursday, May 14th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $12.50.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.